Department of Medicine, Tisch Cancer Center, Mount Sinai School of Medicine, New York, NY 10029, USA.
Haemophilia. 2009 Sep;15(5):1014-21. doi: 10.1111/j.1365-2516.2009.02036.x. Epub 2009 Jun 1.
The emergence of a population of relatively healthy adults with severe haemophilia A presents a unique challenge for haemophilia care in the 21st century. Understanding how best to continue, restart, initiate or modify prophylaxis in younger and older adult patients is essential to optimizing their care. To elucidate practice and outcome data, a survey was sent to 23 US hemophilia treatment centers (HTCs); 10 centers responded, providing data concerning up to 145 adults (mean age of 34 years). Forty-eight patients (33%) were on regular prophylaxis when first seen at the HTC; the prophylactic regimen was modified for 22/48 (46%), often because of breakthrough bleeding. Five of 21 patients (24%) for whom data were available discontinued prophylaxis. Three of those five patients (60%) experienced increased bleeding episodes and the other two (40%) subsequently resumed regular prophylactic infusions because of the increased bleeding. Of the 77 patients not initially receiving prophylaxis for whom data were available, prophylaxis was started or resumed in all. The prophylactic regimen was modified in 57/77 patients (74%) at some point during treatment, often because of breakthrough bleeding. Of the 55 patients whose prophylactic regimens were modified for whom data were available, 22 (40%) discontinued prophylaxis. Thirteen of 20 patients (65%) for whom data were available experienced an increase in bleeding episodes and 7/18 patients (39%) who had discontinued prophylaxis and for whom data were available subsequently resumed regular prophylactic infusions because of bleeding. These findings suggest that prophylaxis prevents bleeding in adults with severe haemophilia A and that discontinuation of the prophylactic regimen is associated with increased bleeding events.
在 21 世纪,大量相对健康的重度血友病 A 患者的出现给血友病的治疗带来了独特的挑战。了解如何最好地继续、重新开始、启动或调整年轻和老年成年患者的预防治疗方案对于优化他们的治疗至关重要。为了阐明实践和结果数据,向 23 家美国血友病治疗中心(HTC)发送了一份调查;10 家中心做出了回应,提供了多达 145 名成人的数据(平均年龄为 34 岁)。48 名患者(33%)在首次到 HTC 就诊时接受常规预防治疗;22/48(46%)患者的预防性治疗方案进行了调整,通常是因为突破性出血。21 名患者中有 5 名(24%)的数据可用,其中 5 人中有 3 人(60%)停止了预防治疗。这 3 人(60%)因出血增加而停止预防治疗,另外 2 人(40%)随后因出血增加而恢复常规预防性输注。在可用数据的 77 名未接受初始预防治疗的患者中,所有人都开始或重新开始预防治疗。在治疗过程中的某个时间点,77 名患者中有 57 名(74%)修改了预防方案,通常是因为突破性出血。在可用数据的 55 名预防方案修改的患者中,有 22 名(40%)停止了预防治疗。20 名可用数据的患者中有 13 名(65%)出血事件增加,18 名停止预防治疗的患者中有 7 名(39%)因出血增加而重新开始常规预防性输注。这些发现表明预防治疗可预防重度血友病 A 成人的出血,并且停止预防治疗方案与出血事件增加相关。